School of Translational Health Sciences, University of Bristol, Bristol, UK.
University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Trials. 2020 Oct 21;21(1):873. doi: 10.1186/s13063-020-04798-x.
When planning a multicentre clinical trial, it can be difficult to predict the time needed to open individual sites, and this in turn impacts on the total number of sites needed, the budget and the time frame for a clinical trial to be delivered successfully. This is of particular importance for funding applications with a limited time frame and budget such as NIHR RfPB. It is more efficient and cost-effective to open the total number of sites needed at the outset of a trial, rather than to respond later to slow site opening and recruitment. Here, we share our experience of successfully delivering a multicentre clinical trial for a rare disease within a limited time frame and budget by approximately doubling the number of sites initially predicted to be needed. We initially predicted 20 sites would be needed to deliver the clinical trial, but early on in the trial, the number of sites was more than doubled to allow successful recruitment of the target sample size within the desired time frame. Of the 48 ethically approved sites, the median time from ethical approval of a site to opening for recruitment was 182 days (95% confidence interval [143 to 245 days]) and ranged from 18 to 613 days. In four (9%) of these sites, part of the delay was due to pharmacy sign off not being given when R&D had issued capacity and capability (C&C). Delays due to pharmacy sign off varied from 10 days to over 3 months delay in two sites (94 days and 102 days). A mathematical solution to the problem of planning a study with a short recruitment window has been given to support the planning and costing of grants with fixed time constraints: number of sites = required sample size divided by (number of eligible patients per site per month times recruitment rate times (the number of months accrual minus 6 months)). We expect these results to help others who are planning multicentre clinical trials in the UK. Ethical approval from NRES Committee South West (IRAS number 225959). TRIAL REGISTRATION: EudraCT Number 2017-001171-23 . Registered on 26 June 2017.
在规划多中心临床试验时,很难预测每个中心的开放时间,而这反过来又会影响所需的中心总数、预算以及临床试验成功交付的时间框架。对于具有有限时间框架和预算的资助申请,如 NIHR RfPB,这一点尤为重要。在试验开始时就开设所需的全部中心比后期应对中心开设缓慢和招募缓慢更为高效和具有成本效益。在这里,我们分享了在有限的时间框架和预算内成功交付一项罕见病多中心临床试验的经验,即将最初预测所需的中心数量增加近一倍。我们最初预测需要 20 个中心来开展临床试验,但在试验早期,中心数量增加了一倍以上,以便在所需的时间内成功招募到目标样本量。在 48 个经伦理批准的中心中,从中心获得伦理批准到开始招募的中位数时间为 182 天(95%置信区间[143 至 245 天]),范围为 18 至 613 天。在其中的 4 个中心(9%),部分延迟是由于研发部门发布了能力和条件(C&C),而药房尚未签署同意书。由于药房签署同意书而导致的延迟时间从 10 天到两个中心的超过 3 个月不等(94 天和 102 天)。对于具有较短招募窗口的研究规划问题,已经给出了一个数学解决方案,以支持具有固定时间限制的资助的规划和成本核算:中心数量=所需样本量除以(每个中心每月每个符合条件的患者人数乘以招募率乘以(入组月份减去 6 个月的时间))。我们希望这些结果能帮助其他在英国规划多中心临床试验的人。获得 NRES 委员会西南(IRAS 编号 225959)的伦理批准。临床试验注册:EudraCT 编号 2017-001171-23。于 2017 年 6 月 26 日注册。